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In humans and non-obese diabetic (NOD) mice, insulin au-
toreactivity is a prominent feature during the initiation and 
progression of type 1 diabetes (T1D; Nakayama et al., 2005; 
Zhang et al., 2008; Mohan et al., 2010; Unanue, 2014). Insulin 
autoantibodies (IAAs) are used as important predictive bio-
markers for disease susceptibility and prognosis (Zhang and 
Eisenbarth, 2011). Although IAAs can be of the IgM or IgG 
class (Bodansky et al., 1986; Dean et al., 1986), IgG IAAs are 
associated with robust diabetes progression (Achenbach et al., 
2004; Hoppu et al., 2004). These findings point to an essential 
role of CD4 T helper cells in supporting generation of class-
switched IAAs through cognate interactions with anti-insulin 
B cells. However, issues concerning the source of T cell help, 
the nature of the T cell–B cell interaction, and the sites of 
IAA production remain largely unexplained.
In this study, we have examined the interactions between 
insulin-reactive T and B cells in NOD mice with a goal of iden-
tifying the nature and sites of T cell–B cell interactions and their 
consequences. We previously identified CD4 T cells to insulin 
that escaped thymic negative selection, entered islets of Langer-
hans, and caused diabetes, of which the 8F10 T cell, used here as 
a TCR transgenic mouse, is representative (Mohan et al., 2013). 
The 8F10 mice had IAAs in relatively high titers directed to 
conformational insulin, but these T cells specifically recognize 
the 12–20 sequence of the insulin B chain (B:12-20), an epitope 
that is not presented from the processing of insulin (Mohan et al., 
2011, 2013). Insulin processing by APCs, including B cells, gen-
erates a close but distinct sequence; that is, from 13–21 (B:13-21), 
a one–amino acid shift in the MHC-binding register (Mohan 
et al., 2011). However, the B:12-20 epitope is presented in is-
lets from secretory granules containing catabolites of insulin that 
are transferred to intra-islet resident APCs (Mohan et al., 2010; 
Vomund et al., 2015). Studying this CD4 T cell is important for 
two reasons. First, because a majority of the insulin-reactive T 
cells recognize the B:12-20 epitope (Mohan et al., 2010, 2011), 
it remains to be defined how this T cell can interact with anti-in-
sulin B cells and support IAA production when B cells that take 
up insulin should not present it. Second, it considers where the 
interaction is taking place; that is, whether insulin presentation 
is restricted to the pancreatic LNs (pLNs) or extended to other 
peripheral sites. The present view is that the pLN that drains the 
islets is a key site for the autoimmune process to move forward 
(Höglund et al., 1999; Gagnerault et al., 2002; Levisetti et al., 
2004). Insulin circulates at low picomolar levels, an amount that 
is most likely below a threshold for effective T cell–B cell in-
teractions outside the islet–pLN axis. But, notably, endogenous 
insulin has been shown to have an effect in modulating imma-
ture anti-insulin B cells in the bone marrow (Henry et al., 2009; 
Henry-Bonami et al., 2013) and mature B cells in the spleen 
(Rojas et al., 2001; Acevedo-Suárez et al., 2005).
Examining anti-insulin T cell–B cell interaction is hin-
dered by the difficulty of tracking the insulin specificity in 
the polyclonal BCR repertoire. This limitation can be over-
come by the VH125.NOD anti-insulin BCR heavy chain 
transgenic model developed by one of us (Rojas et al., 2001). 
The VH125 BCR heavy chain pairs with various endogenous 
light chains, giving rise to 1–3% insulin-specific B cells of the 
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repertoire (Hulbert et al., 2001; Henry-Bonami et al., 2013). 
A recent study directly targeted the rearranged VH125 vari-
able region genes into the endogenous IgH locus (Williams 
et al., 2015). Consequently, the anti-insulin B cells formed 
in the resulting VH125SD mice are capable of class-switch re-
combination, permitting assessment of the IgG class of IAAs.
In this study, the 8F10 and VH125SD mouse strains were 
crossed and examined. The 8F10 T cells provided help to anti- 
insulin B cells, leading to germinal center (GC) formation 
and IAA production. The T cell–B cell interaction took place 
because activated GC B cells acquired altered insulin process-
ing, resulting in presentation of the B:12-20 epitope to 8F10 
T cells. Furthermore, insulin-specific GC formation was ob-
served in multiple LNs and spleens, most likely resulting from 
the low level of insulin in the blood or lymph.
RES ULTS
Two approaches to study the interactions between insulin-
specific CD4 T cells and B cells
Insulin-specific T cell–B cell interactions were examined in 
two complementary models. In one, we crossed 8F10 TCR 
transgenic mice with the VH125SD.NOD BCR transgenic 
mice. In this model, the pathogenicity of 8F10 T cells was 
suppressed by strong regulatory mechanisms that prevented 
spontaneous diabetes. Our previous study showed that the 
8F10 mice developed diabetes only when crossed onto the 
Rag1−/− background that excludes TCR α-chain rearrange-
ment and T regulatory cell (T reg cell) development (Mohan 
et al., 2013). As shown in Fig. 1 A, none of the female 8F10-
VH125SD mice developed diabetes, whereas the nontransgenic 
(Tg−/−) littermates did. Indeed, experiments in progress in-
dicate that treatment of these mice with anti-CD25 (PC61) 
antibody resulted in diabetes development in three out of five 
mice, whereas no mice under the isotype control antibody 
treatment became diabetic (Fig. 1 B).
At 8 wk of age, the islets of the 8F10-VH125SD mice 
displayed a heterogeneous profile of inflammation, as mani-
fested by coexistence of peri-insulitic and mild intra-insulitic 
lesions (Fig. 1, C and D). Flow cytometry analyses revealed a 
significantly lower frequency of CD45+ leukocytes infiltrat-
ing the islets of 8F10-VH125SD mice relative to Tg−/− litter-
mates (Fig. 1 E). Furthermore, infiltration of CD103+ DCs, a 
Figure 1. Diabetes development and islet 
infiltration in the 8F10-VH125SD mice. 
(A) Percentage of diabetes-free age-matched 
female mice in nontransgenic (Tg−/−) and 
8F10-VH125SD strains. (B) Percentage of diabe-
tes-free 8F10-VH125SD mice given anti-CD25 
(PC61) antibody or control rat IgG treatment. 
The arrows indicate the time point of anti-
body administration. (C–H) Islets from 8-wk-
old female nontransgenic and 8F10-VH125SD 
mice were analyzed. (C) Hematoxylin and 
eosin staining of pancreatic sections from the 
8F10-VH125SD mice showing representative 
healthy and peri-insulitic islets. (D) Hematox-
ylin and eosin staining of pancreatic sections 
from 8F10-VH125SD mice showing healthy and 
mild intra-insulitic islets. Bars, 50 µM. (E) FACS 
plots (left) and quantification (right) show-
ing the frequency of the CD45+ leukocytes 
among total islet cells (gated on live and sin-
glets). (F) FACS plots (left) and quantification 
(right) showing the frequency of the CD103+ 
DCs in CD45+CD11c+ gated islet cells. (G) FACS 
plots (left) and quantification (right) showing 
the frequency of the CD4+ and B220+ cells in 
CD45+ gated islet cells. (H) FACS plots (left) and 
quantification (right) showing the frequency 
of the FoxP3+ cells among CD45+CD4+CD8− T 
cells in the pLN and islets of the 8F10-VH125SD 
mice. *, P < 0.05; **, P < 0.005; Mann-Whitney 
test. Each point in E–H represents results of 
individual mice obtained from three indepen-
dent experiments (mean ± SEM).
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process required for diabetes development (Ferris et al., 2014), 
was also limited in the double transgenic mice (Fig. 1 F). In-
filtration by the B220+ B cells was significantly less in the 
8F10-VH125SD than the Tg−/− littermates (Fig. 1 G). FoxP3+ 
T reg cells were found in the pLN, and more strikingly, a sig-
nificantly higher number of CD4+ T cells in the islets of the 
8F10-VH125SD mice were FoxP3 positive (Fig. 1 H).
The second model consisted of transferring naive T cells 
(CD4+CD8−B220−CD25−CD62LhiCD44−) isolated from 
8F10.Rag1−/− mice and B cells (CD19+CD4−CD8−IgMa+ 
GL7−IgG−) from the VH125SD mice into NOD.Rag1−/− re-
cipients. Under this approach, diabetes developed. Transfer of 
VH125SD B cells did not induce diabetes during a 50-d mon-
itoring period (Fig.  2  A). Transfer of 8F10.Rag1−/− T cells 
alone or together with B cells from conventional NOD mice 
induced diabetes with a similar kinetics (Fig. 2 A). Conven-
tional NOD B cells did not exacerbate diabetes transfer, pos-
sibly because of a low number of anti-insulin B cells in the 
repertoire. Indeed, B cells from the VH125SD mice significantly 
enhanced the ability of 8F10.Rag1−/− T cells to drive diabetes 
(Fig. 2 A). These results indicate the importance of anti-insulin 
T cell–B cell cooperation in promoting diabetes development, 
in agreement with previous studies showing the capacity of the 
VH125 BCR in exacerbating diabetes (Hulbert et al., 2001).
IAA production in the two models
The sera of the 8F10-VH125SD mice contained the highest 
titers of IAAs across the IgG1, IgG2a, and IgG2b subclasses 
relative to the 8F10, VH125SD, and Tg−/− littermates (Fig. 2 B, 
left). Low levels of IAAs with each IgG subclass were found in 
the Tg−/− and VH125SD mice (Fig. 2 B, left). Most of the IAAs 
in the 8F10 mice were IgG1, with some moderate levels of 
IgG2b (Fig. 2 B, left). Importantly, the IAAs were blocked by 
excess free insulin, indicating their specificity to conforma-
tional insulin (Fig. 2 B, right). Antibodies to denatured insulin 
or free 9–23 peptide were not detected (not depicted). Thus, 
8F10 T cells promote production of class-switched IAAs rec-
ognizing native insulin.
Figure 2. Anti-insulin T cell–B cell interaction 
exacerbates diabetes transfer and leads to pro-
duction of IAAs. (A) Incidence of diabetes in NOD.
Rag1−/− recipients given the indicated combina-
tions of T and/or B cells. FACS-sorted naive T cells 
(CD4+CD8−B220−CD25−CD62LhiCD44−) from 8F10.
Rag1−/− mice were transferred with or without B 
cells (CD19+CD4−CD8−IgMa+GL7−IgG−) sorted from 
VH125SD or WT NOD mice. ***, P < 0.0005; log-rank 
test. (B) Titers and specificity of IAAs in 8F10-VH125SD 
double transgenic mice. Sera collected from 4–9-wk-
old 8F10-VH125SD mice were pooled, serially diluted, 
and examined by ELI SA. Sera from age-matched lit-
termates, including nontransgenic (Tg−/−), 8F10, and 
VH125SD single transgenic mice, were also examined. 
To determine the specificity of IAAs, one aliquot of 
sera was incubated with a 10-fold excess of insulin 
(right) before measurement. (C) ELI SA assays in sera of 
NOD.Rag1−/− recipients given indicated combinations 
of T and/or B cells sorted as in A. FACS-sorted naive 
BDC2.5 T cells (CD4+CD8−B220−CD25−CD62LhiCD44−) 
were transferred as controls. The sera were collected 
on day 30 after transfer, and each symbol represents 
an individual mouse. *, P < 0.05; **, P < 0.005; ***, 
P < 0.001; Mann-Whitney test. Data represent cu-
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In the second model of NOD.Rag1−/− mice transferred 
with 8F10.Rag1−/− T cells plus VH125SD B cells, diabetes de-
veloped with concomitant IAA production encompassing 
IgG1, IgG2a, and IgG2b subclasses (Fig. 2 C). These mice had 
significantly higher titers of IAAs than NOD.Rag1−/− recip-
ients of 8F10.Rag1−/− T cells alone or 8F10.Rag1−/− T cells 
plus WT B cells (Fig. 2 C). The IAAs specifically recognized 
native insulin as indicated by their inhibition with free insulin 
(Fig. 2 C). Of note, the non–insulin-reactive BDC2.5 T cells, 
when cotransferred with VH125SD B cells, did not induce IAA 
production (Fig. 2 C). Thus, in the T cell–B cell cotransfer 
model, IAAs originate from specific anti-insulin T cell–B cell 
interactions that promote diabetes progression.
GC B cells in the presence of 8F10 T cells
The high titer of class-switched IAAs in the 8F10-VH125SD 
mice indicates active insulin-specific GC responses. We ex-
amined the B cells from the pLN for their reactivity to 
insulin by flow cytometry. The GC (GC+) B cells were 
defined as CD19+FashiIgDloGL7+ and the non-GC (GC−) 
B cells as CD19+FasloIgDhiGL7− (Fig.  3  A). Insulin-spe-
cific B cells were identified by their binding to bioti-
nylated insulin in the presence or absence of a 10-fold 
excess of unlabeled insulin.
Strikingly, 45% of the GC+ B cells in the pLNs of the 
8F10-VH125SD mice bound insulin, and the binding was 
completely blocked by excess soluble insulin (Fig. 3 B, right). 
The non-GC insulin-binding B cells were few in the 8F10-
VH125SD (2.8%) mice, consisting of two sets distinguished by 
the mean fluorescence intensities of the biotinylated insulin 
staining (Fig.  3  C, top). This is likely because the VH125SD 
BCR heavy chain pairs randomly with endogenous light 
chains, giving rise to BCRs with different affinities to insulin 
(Henry et al., 2010; Henry-Bonami et al., 2013). In contrast, 
very few B cells in the GCs of the 8F10 (0.1%) and VH125SD 
(0.3%) mice bound insulin (Fig. 3 B). Quantification of mul-
tiple experiments showed that the frequency of the insu-
lin-binding B cells in the GCs of the 8F10-VH125SD mice 
was significantly higher than the 8F10 and VH125SD mice, 
whereas the GC− insulin-binding B cells were comparable 
between the 8F10-VH125SD and VH125SD mice (Fig.  3  D). 
Thus, anti-insulin B cells are specifically selected into GCs 
from a polyclonal repertoire, where in the presence of 8F10 
T helper cells, they underwent a 10–30-fold expansion, cor-
relating with the high titers of IAAs.
Systemic generation of anti-insulin GCs
We next examined such insulin-specific GC formation in 
other lymphoid organs and found that the mesenteric LNs 
(mLNs), inguinal (iLNs), and axillary LNs (aLNs) contained 
20–50% of insulin-binding B cells (Fig. 4 A, top). The fre-
quency of the insulin-binding B cells in the GCs of the mLN, 
iLN, and aLN was comparable with pLN (Fig. 4 B). The GCs 
in the spleen had a moderate number (12%) of insulin-bind-
ing B cells (Fig. 4 A, top). In contrast, anti-insulin B cells only 
constituted a small fraction (≤3%) of the GC− B cells in all 
of the lymphoid organs (Fig.  4  A, bottom). Therefore, the 
development of insulin-specific GCs was systemic, indicating 
that the very low level of insulin in blood or lymph (Rasio 
et al., 1967; Yang et al., 1989) must serve as the source of 
the GC B cell responses.
To evaluate class-switch recombination, we assessed 
surface IgMa and IgG expression on the GC+ anti-insulin 
(GC+INS+) B cells as well as the non-GC B cells with high 
and low insulin-binding mean fluorescence intensities (des-
ignated as GC−INShi and GC−INSlo, respectively; gated ac-
cording to Fig. 4 C). Strikingly, class-switched (IgG+IgMa−) 
B cells (24–45%) were only found in the GC+INS+ B cell 
subset in all the lymphoid sites (Fig. 4 D, top), whereas the 
GC−INSlo and GC−INShi B cells had very few IgG-bearing 
B cells (1.1–2.7% and 0.4–1%, respectively), and >80% re-
mained IgMa+IgG− (Fig. 4 D, middle and bottom). In addi-
tion, many of the IgG-negative GC+INS+ B cells (42–59%) 
had decreased surface IgMa expression (IgMalo), perhaps 
representing B cells initiating class-switch recombination 
(Fig. 4 D, top). This IgG−IgMalo population was largely absent 
in the GC−INSlo (3.1–4.2%) and GC−INShi (0.3–1.2%) sub-
Figure 3. 8F10 T cell help is essential for GC differentiation of an-
ti-insulin B cells. (A) Gating strategy of GC+ and GC− B cells. (B and C) 
Insulin binding of the GC+ (B) and GC− (C) B cells from the pLNs of the 8F10, 
VH125SD, and 8F10-VH125SD mice. The insulin-binding B cells were identified 
by staining with biotinylated insulin followed by fluorochrome-conjugated 
streptavidin (top), and the specificity of insulin binding was determined by 
adding 10× insulin (bottom). (D) Quantification of the frequency of insu-
lin-binding B cells among the GC− or GC+ B cells (mean ± SEM) as assessed 
in B and C. *, P < 0.05; Mann-Whitney test. Data in A–C are representa-
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sets (Fig. 4 D, middle and bottom). Thus, anti-insulin B cells 
that differentiated into the GC stage are competent to class 
switch, correlating with the various IgG subclasses of IAAs.
The finding of systemic anti-insulin GC formation was 
also observed in NOD.Rag1−/− recipients of 8F10.Rag1−/− 
T cells plus VH125SD B cells. Specifically, GC responses were 
found in the pLN, mLN, and spleen of these mice on day 20 
after transfer (Fig. 4 E). More importantly, the GL7+ B cells 
were exclusively insulin specific, further confirming that only 
anti-insulin B cells can be selected into GCs by the 8F10.
Rag1−/− T cells. When naive BDC2.5 T cells were transferred 
with VH125SD B cells, they triggered GC reactions only in the 
pLN, but none of the GL7+ B cells bound insulin (Fig. 4 E). 
These results confirm that 8F10 T cells directly help insu-
lin-specific B cells to form GCs by using native insulin pre-
sented in multiple lymphoid organs.
8F10 T cells differentiate into functional T follicular 
helper cells (Tfh cells)
Corresponding with the systemic anti-insulin GC responses, 
development of Tfh cells was found in various LNs of the 
8F10-VH125SD mice (Fig. 5). This was evident by finding CD4 
T cells expressing CXCR5 and PD-1, a feature indicating Tfh 
lineage commitment (Fig. 5 A). RT-PCR analyses revealed 
that FACS-sorted Tfh cells but not naive T cells expressed 
genes encoding CXCR5 (cxcr5), PD-1 (pdcd1), and Bcl-6 
Figure 4. Anti-insulin GC formation occurs in multiple lymphoid organs. (A) Insulin binding of the GC+ and GC− B cells (gated according to Fig. 3 A) 
isolated from the pLNs, mLNs, iLNs, and aLNs as well as spleens of the 8F10-VH125SD mice. (B) Quantification of the frequency of the insulin-binding B cells 
among GC+ B cells (mean ± SEM) in multiple sites as assessed in A. ns, not significant; Mann-Whitney test. (C) Gating strategy of the GC+INS+, GC−INSlo, and 
GC−INShi B cells isolated from the 8F10-VH125SD mice. (D) Surface staining of IgG and IgMa on the GC+INS+, GC−INSlo, and GC−INShi B cells from the indicated 
lymphoid sites of 8F10-VH125SD mice. (E) GL7 expression and insulin binding on B cells (gated on CD19+CD4−CD8−) from NOD.Rag1−/− recipients given FACS-
sorted VH125SD B cells alone or together with naive BDC2.5 or 8F10.Rag1−/− T cells. The NOD.Rag1−/− recipients were killed on day 20 after transfer. Data in 
A and C–E are representative of three to six independent experiments, and each symbol in B represents one individual experiment.
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(bcl6; Fig. 5 B, top). The Tfh cells also highly expressed genes 
encoding CD40 ligand (cd40lg), IL-4 (il4), and IFN-γ (ifng; 
Fig. 5 B, bottom). In the transfer model, naive 8F10.Rag1−/− 
T cells differentiated into CXCR5hiPD-1hi Tfh cells in the 
pLNs, mLNs, and spleen when cotransferred with VH125SD B 
cells (Fig. 5 C). Collectively, these results suggest that 8F10 T 
cells differentiate into committed Tfh cells capable of provid-
ing key mediators shaping GC responses and antibody iso-
types (Garside et al., 1998; Takahashi et al., 1998; Reinhardt et 
al., 2009; Crotty, 2011; Victora and Nussenzweig, 2012).
Insulin-specific GC B cells have altered insulin processing 
and presentation pathways
8F10 T cells specifically recognize the B:12-20 epitope 
that binds weakly to I-Ag7. This peptide segment is edited 
off when insulin is processed by APCs (Mohan et al., 2011). 
The findings that 8F10 T cells sustain GC B cell responses 
and promote conformation-specific antibodies raised a co-
nundrum. It suggested that GC B cells may have altered in-
sulin-processing mechanisms that allow presentation of the 
12–20 epitope to 8F10 T cells.
FACS-sorted GC+INS+ cells from the 8F10-VH125SD 
mice were tested for presentation of insulin epitopes. In par-
allel, the GC−INSlo and GC−INShi B cells were also sorted 
and examined. We tested with the 8F10 T cell hybridoma that 
only recognizes the B:12-20 epitope from pulsing APCs with 
peptide or denatured insulin but is unreactive to APCs pulsed 
with insulin (Mohan et al., 2011). The IIT-3 hybridoma spe-
cific for the B:13-21 epitope from processing of insulin was 
tested in parallel (Mohan et al., 2011). Both T cells recognize 
the B:9-23 peptide that contains both registers.
All of the three B cell subsets pulsed with the B:9-23 
peptide robustly stimulated both T cells (Fig. 6 A), indicat-
ing their expression of I-Ag7 molecules. Each B cell subset 
pulsed with insulin activated the IIT-3 T cells, indicating that 
they generated the stronger MHC-binding B:13-21 epitope 
during insulin processing (Fig. 6 A). Although the GC−INShi 
and GC−INSlo B cells pulsed with insulin were unable to 
stimulate the 8F10 T cells, consistent with our previous ex-
periments (Mohan et al., 2010, 2011), the GC+INS+ B cells 
activated 8F10 T cells (Fig. 6 A). Notably, when five times 
more insulin-pulsed non-GC B cells were used to stimulate 
8F10 T cells, a weak response was induced by the GC−INSlo 
but not the GC−INShi B cells (Fig. 6 B).
The findings that the GC+INS+ B cells (gated according 
to Fig. 6 C) presented the B:12-20 epitope to 8F10 T cells 
were confirmed in the transfer model (Fig.  6 D). The low 
recovery of B cells in this model did not permit further frac-
tionation of the GC−INShi and GC−INSlo B cells. Instead, the 
non–insulin-binding B cells outside GCs (GC−INS−) were 
analyzed (gated according to Fig. 6 C), and this set was unable 
to activate 8F10 T cells upon insulin pulse (Fig. 6 D).
These results suggest that B cell activation changes 
the selection of insulin epitopes. To examine this further, 
we established a cell culture system in which anti-insulin 
B cells were treated with various stimuli and then tested 
with the IIT-3 or 8F10 T cell hybridomas for the response 
to insulin (Fig.  7, A and B). Because of the difficulties in 
recovering sufficient anti-insulin B cells from the VH125SD 
mice, we examined B cells isolated from the 125Tg mice 
that harbor transgenes expressing the anti-insulin VH125 and 
Vκ125 chains, giving rise to a monoclonal BCR repertoire 
in which >98% of B cells were insulin specific (Rojas et 
al., 2001). Without stimulation, the 125Tg B cells presented 
insulin to IIT-3 but not 8F10 T cells, indicating that they 
behaved like unstimulated B cells; that is, capable of pre-
senting the B:13-21 but not the B:12-20 epitope (Fig. 7 A, 
media). Polyclonal B cells isolated from NOD mice likewise 
presented insulin to IIT-3 but not to 8F10 T cells (Fig. 7 B, 
media). The responses in general were considerably weaker 
Figure 5. 8F10 T cells differentiate into functional Tfh cells. (A) FACS 
plots showing surface CXCR5 and PD-1 staining on CD4+CD8−Vβ8.1/8.2+C-
D62Llo T cells from LNs of 8F10-VH125SD mice. (B) RT-PCR analysis of 
FACS-sorted Tfh (CD4+CD8−B220−CD25−CD62LloCXCR5hiPD-1hi) and naive 
T (CD4+CD8−B220−CD25−CD62LhiCD44−) cells from pooled LNs of 8F10-
VH125SD mice. (C) FACS-sorted naive 8F10.Rag1−/− T cells were transferred 
into NOD.Rag1−/− recipients along with VH125SD B cells. The FACS plots 
show surface staining of CXCR5 and PD-1 on the naive 8F10.Rag1−/− T 
cells before transfer and on CD4+CD8−Vβ8.1/8.2+B220− gated T cells re-
covered from NOD.Rag1−/− recipients on day 20. Data represent cumu-
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than those induced by the 125Tg B cells, signifying a less 
efficient insulin uptake by WT B cells.
The 125Tg and WT B cells were cultured with the 
stimuli indicated in Fig. 7 (A and B). 8F10 T cells responded 
weakly to 125Tg B cells stimulated with soluble CD40 ligand 
(CD40L) or IL-4 alone, but these two stimuli in combina-
tion enabled a strong activation (Fig. 7 A, CD40L + IL-4). 
Importantly, the cytokine IL-4 was the major molecule en-
suring the presentation of the B:12-20 epitope, as indicated 
by the fact that 125Tg B cells stimulated by LPS combined 
with IL-4 (LPS + IL-4) but not LPS alone activated 8F10 T 
cells (Fig. 7 A, bottom). We examined other factors that can 
Figure 7. B cells stimulated by CD40L and IL-4 are able to present the B:12-20 epitope when processing insulin. (A and B) Response of the IIT-3 
and 8F10 T cell hybridomas to 125Tg (A) or WT NOD (B) B cells after stimulation and insulin pulse. The 125Tg and WT NOD B cells were stimulated with the 
indicated treatments for 18 h and were cultured with serially diluted concentrations of insulin in the presence of the IIT-3 or 8F10 T cell hybridomas. Data 
are representative of three independent experiments.
Figure 6. Insulin-specific GC B cells dis-
play an altered pathway for insulin pro-
cessing and presentation. (A and B) Response 
of the IIT-3 and 8F10 T cell hybridomas to the 
GC−INShi, GC−INSlo, and GC+INS+ B cells FACS 
sorted from the 8F10-VH125SD mice and pulsed 
with the B:9-23 peptide or insulin. *, P < 0.05; 
**, P < 0.05; paired Student’s t test. (C) Sorting 
strategy of the GC+INS+ and GC−INS− B cells 
from NOD.Rag1−/− recipients of naive 8F10.
Rag1−/− T cells plus VH125SD B cells on day 20. 
(D) Response of the IIT-3 and 8F10 T cell hybrid-
omas to the GC+INS+ and the GC−INS− B cells 
FACS sorted as in C and pulsed with the B:9-23 
peptide or insulin. **, P < 0.05; paired Student’s 
t test. The B cells (APCs) were used as 2 × 104 
per well (A and D) or 105 per well (B). Data in 
A, B, and D represent cumulative results from 
three independent experiments (mean ± SEM).
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be provided by Tfh cells, including the cytokine IL-21 (Lint-
erman et al., 2010; Zotos et al., 2010) and IFN-γ (Reinhardt 
et al., 2009). Neither of these two cytokines combined with 
CD40L (CD40L + IL-21 and CD40L + IFN-γ, respectively) 
further enhanced activation of 8F10 T cells (Fig. 7 A, bottom). 
Of note, 8F10 T cells responded positively to conventional B 
cells stimulated by CD40L + IL-4 or LPS + IL-4 at the high-
est concentration of insulin pulse (Fig. 7 B, bottom). Thus, T 
cell helper signals, particularly CD40L and IL-4 in synergy, 
not only function as key mediators regulating GC function 
but also influence antigen presentation pathways in cognate B 
cells to ensure optimal and broader T cell–B cell interactions.
DIS CUS SION
There are three relevant findings made here that are import-
ant for understanding the pathobiology of autoimmune dia-
betes. First, class-switched IAAs can originate from dynamic 
interactions between anti-insulin B cells and a unique set of 
insulin-reactive T cells that recognize the B:12-20 epitope. 
Second, the native insulin molecule is being presented and 
recognized by T and B cells in multiple lymphoid sites, indi-
cating that the islet–pLN axis is not the only location capable 
of fostering insulin autoreactivity. Third, activated B cells, in 
particular GC B cells, are able to present a broader reper-
toire of insulin peptides.
Aberrant Tfh cell responses have been associated with 
autoimmune diseases, including T1D (Vinuesa et al., 2005; 
Kenefeck et al., 2015; Ueno et al., 2015). In line with this, 
we found that 8F10 T cells differentiated into Tfh cells and 
promoted IAA production. These findings revealed a new 
layer of the functionality of these T cells and largely explained 
the origin of class-switched IAAs in autoimmune diabetes. In 
our previous studies, 8F10 T cells escaped thymic selection 
and were directly recruited into the islets bypassing the pLN 
(Mohan et al., 2011, 2013). In this study, we observed 8F10 
T cell reactivity in peripheral LNs, pointing to recognition of 
peptide–MHC complexes. It is possible that this recognition 
is mediated by a subset of resident APCs that can constitu-
tively present the B:12-20 epitope upon insulin processing or 
by migratory APCs that are activated in the islets or pLN. The 
B:12-20 epitope may also be available through the presen-
tation of free insulin peptides by all APC subsets expressing 
MHC II molecules, although whether insulin peptides can be 
found in the lymph or blood remains to be determined. Dis-
secting these events may further reveal how naive 8F10 T cells 
differentiate into effector or Tfh cells in LNs and whether 
such processes impose pathogenic outcomes. Above all, 8F10 
Tfh cells are competent helper cells, as manifested by their 
expression of Tfh linage markers and T cell help factors. The 
result that CD40L in combination with IL-4 allowed optimal 
presentation of the B:12-20 epitope provided a mechanism by 
which GC B cells interact with 8F10 T cells. Because CD40L 
and IL-4 also reversed the anergy of anti-insulin B cells 
(Acevedo-Suárez et al., 2005), our findings propose a model 
in which signaling events relevant to T cell help, tolerance 
breakdown, and altered antigen presentation pathways are in-
tegrated to ensure anti-insulin GC responses. The mode of 
action of CD40L plus IL-4, such as regulation of H2-DM and 
H2-DO expression, is a subject of intense research at present.
The finding of systemic immunoreactivity to insulin in-
dicates that the low concentration (∼100 pM) of circulating in-
sulin is sufficient to support GC reactions, even in the spleen, an 
organ lacking lymphatics. Insulin is also found in lymph (Rasio 
et al., 1967; Yang et al., 1989) and may enter LNs into the sub-
capsular sinus to make it available to anti-insulin B cells in the 
follicles, like other small soluble proteins (Gretz et al., 2000; 
Pape et al., 2007; Batista and Harwood, 2009; Roozendaal et al., 
2009). Therefore, in these instances, spontaneous GC forma-
tion may be dependent on persistent availability of a self-anti-
gen rather than on a high concentration. The finding of insulin 
presentation throughout the lymphoid system should be ex-
trapolated to other endocrine autoimmune diseases in which 
hormones are the target antigen. The systemic presentation 
of the hormone could be relevant in two contexts, as in here, 
where strong CD4 T cell autoreactivity results in B cell activa-
tion and autoantibody formation. But also such presentation 
may be modulatory and may control the activation of both T 
and B cells (Goodnow et al., 1988; Adelstein et al., 1991; Cooke 
et al., 1994; Rojas et al., 2001; Acevedo-Suárez et al., 2005; 
Henry et al., 2009; Zikherman et al., 2012; Kendall et al., 2013).
On the cellular basis, cognate T cell–B cell interactions 
are required for anti-insulin GC formation. It has been sug-
gested that T cell help is a critical limiting factor for GC se-
lection (Victora et al., 2010) and that GC B cells presenting 
high amounts of antigens are selectively expanded by Tfh 
cells (Gitlin et al., 2014). Our results reinforced this no-
tion by showing that the GC+INS+ cells actively presented 
the unconventional B:12-20 epitope, which likely ensured 
optimal interactions with 8F10 Tfh cells. Beyond efficient 
antigen presentation by GC B cells (Glazier et al., 2002), 
our finding further revealed that epitope selection by GC B 
cells is less constrained, allowing presentation of a broader 
repertoire of peptides. On the other hand, cellular events 
concerning how anti-insulin B cells are initially selected 
into GCs are less understood. We detected a weak presen-
tation of the B:12-20 epitope by the GC−INSlo but not the 
GC−INShi B cells. We speculate that this weak response may 
come from rare B cells making initial contact with 8F10 T 
cells before the GC phase, an event that may occur at the 
border of the T cell–B cell zone (Okada and Cyster, 2006). 
This idea is supported by previous data showing that the 
GC−INSlo B cells were functionally more activated than the 
GC−INShi B cells (Kendall et al., 2007; Henry-Bonami et 
al., 2013) and that activation of anti-insulin B cells enabled 
presentation of the B:12-20 epitope.
The cooperativity between anti-insulin T and B cells in 
exacerbation of diabetes transfer is relevant to the role of B 
cells in T1D development. Previous studies have shown ar-
rested diabetes progression in the B cell–deficient (µMT−/−) 
NOD mice (Serreze et al., 1996; Akashi et al., 1997). In gen-
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eral, B cells may contribute to T1D development by func-
tioning as APCs and/or producing anti-islet antibodies. 
Supporting a role of APCs, impaired effector functions of 
CD4 and CD8 T cells were observed in µMT−/− mice (Gree-
ley et al., 2001; Mariño et al., 2012) and in mice with B cell 
depletion (Hu et al., 2007). Moreover, ablation of I-Ag7 in B 
cells significantly reduced diabetes incidence and insulitis se-
verity (Noorchashm et al., 1999). Given that these manipula-
tions also abolished antibody production, a role of antibody in 
these models was not excluded. In fact, anti–hen egg lysozyme 
(HEL) antibodies were able to assist HEL-reactive T cells to 
trigger diabetes in mice expressing HEL in the islets (Silva 
et al., 2011). In another study, diabetic autoimmunity was 
ensured through cooperation between anti-OVA antibodies 
and OVA-specific CD8 T cells (Harbers et al., 2007). In our 
model, IAA production is observed concomitantly with ex-
acerbated diabetes development, implying a role of IAAs in 
assisting T cell responses. Whether IAAs are able to target the 
islet and directly participate in diabetogenesis through mech-
anisms involving complement and Fc-γ receptors (Harbers et 
al., 2007) requires further investigation.
MAT ERI ALS AND MET HODS
Mice. NOD/ShiLtJ (NOD), NOD.129S7(B6)-Rag1tm1-
Mom/J (NOD.Rag1−/−), and NOD.Cg-Tg(TcraBDC2.5, 
TcrbBDC2.5)1Doi/DoiJ (BDC 2.5) mice were obtained 
from The Jackson Laboratory.
The 125Tg mice (on the NOD background) express-
ing anti-insulin BCR heavy and light chain transgenes were 
described previously (Rojas et al., 2001). The VH125SD mice 
that harbor an anti-insulin BCR heavy chain site directed to 
native IgH locus on the C57BL/6 background (Williams et 
al., 2015) were backcrossed onto the NOD background for 
>10 generations. The 8F10 TCR transgenic mice specific for 
the 12–20 fragment of the insulin B chain (VEA LYL VCG; 
Mohan et al., 2013) were crossed with the VH125SD mice to 
generate the 8F10-VH125SD double transgenic mice. Flow 
cytometry analyses confirmed that >95% of B cells in the 
VH125SD and 8F10-VH125SD mice were transgenic (IgMa+). 
The 8F10.Rag1−/− mice were generated by intercrossing the 
8F10 mice with the NOD.Rag1−/− mice. All the mice were 
maintained in specific pathogen-free conditions, and all an-
imal studies were approved by the Division of Comparative 
Medicine of the Washington University School of Medicine.
Antibodies. The following antibodies were purchased from 
BioLegend: PerCP-Cy5.5 anti-B220 (RA3-6B2), PE an-
ti-CD103 (2E7), APC-Cy7 anti-CD11c (N418), PE-Cy7 an-
ti-CD4 (RM4-5), BV510 anti-CD45 (30-F11), PerCP-Cy5.5 
anti-CD8a (53-6.7), APC anti-F4/80 (BM8), APC an-
ti-CXCR5 (L138D7), Brilliant violet 421 anti-PD1 
(29F.1A12), FITC anti-IgMb (AF6-78), PE anti-IgMa (MA-
69), and FITC anti-Vβ8.1/8.2 (KJ16-133.18). The following 
antibodies were purchased from eBioscience: Alexa Fluor 488 
anti-GL7 (GL7), PE-Cy7 anti-IgD (11-26), PerCP-eFluor 
710 anti-Fas (15A7), PE or eFluor 450 anti-CD19 (1D3), 
APC anti-CD25 (PC61.5), FITC anti-CD44 (IM7), and PE 
anti-FoxP3 (FJK-16s). The following antibodies were pur-
chased from BD: PE anti-CD62 ligand (MEL-14), FITC or 
APC anti-CD3e (145-2C11), and FITC anti-Vβ4 (KT4). 
APC-conjugated F(ab′)2 donkey anti–mouse IgG (H+L) was 
purchased from Jackson ImmunoResearch Laboratories, Inc., 
and Pacific blue I-Ag7 (AG2.42.7) was made in our laboratory.
Flow cytometry and cell sorting. Single-cell suspensions were 
treated with FcR-blocking media containing 2.4G2 antibod-
ies. The cells were then stained with fluorescent antibodies on 
ice for 25 min followed by incubation with cell viability dye 
(eBioscience). For detection of insulin-binding B cells, cells 
were incubated with 50 ng/ml biotinylated insulin (Eagle 
Biosciences) with or without inhibition with 500 ng/ml un-
conjugated insulin for 30 min on ice followed by staining 
with APC-conjugated streptavidin (BioLegend) for 15 min. 
The FoxP3 staining was performed using a transcription fac-
tor buffer set (eBioscience). The flow cytometry samples were 
collected using a FAC SCanto II (BD), and data were analyzed 
using FlowJo software (Tree Star). Cell sorting was performed 
using a FAC SAria II (BD).
Islet isolation. The duodenum ampulla was clamped, and the 
pancreas was perfused with 5-ml calcium-free Hank’s bal-
anced salt solution supplemented with 0.4 mg/ml type XI 
collagenase (Sigma-Aldrich) through the common bile duct. 
The pancreases were then removed and digested for 15 min 
at 37°C. After a 90-s shaking, the digestion mixture was 
washed and passed through a 70-µm cell strainer. The is-
let-containing fraction retained by the strainer was flushed 
and stained with 200 mg/ml of the zinc-chelating dye dithi-
zone (Sigma-Aldrich) as a marker of islets. The islets were 
then handpicked and dispersed in Cell Dissociation Solution 
Non-Enzymatic (Sigma-Aldrich) for 3 min at 37°C for 
single-cell suspensions.
Antibody treatment. 4-wk-old female 8F10-VH125SD mice 
were injected with anti-CD25 (PC61) antibody or the iso-
type control Rat IgG i.p. on day 0, 3, 6, and 9 (500 µg per 
injection). The mice were monitored for diabetes devel-
opment for another 30 d.
IAA measurement by ELI SA. 96-well ELI SA plates were 
coated with 1 µg/well of human insulin (Sigma-Aldrich) 
overnight at 4°C and were blocked with 3% BSA in PBS. 
Sera were divided into two equal aliquots that were incubated 
with or without 10 µg/ml insulin on ice for 1 h. The sera 
were then added to insulin-coated plates for incubation over-
night at 4°C. After extensive washes, the plates were incu-
bated with HRP-conjugated goat anti–mouse IgG1, IgG2a, 
and IgG2b antibodies (1:10,000; Jackson ImmunoResearch 
Laboratories, Inc.) for 1 h at room temperature. The enzyme 
reactions were probed by the OptEIA TMB Substrate Re-
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agent Set (BD), and the data were collected using an iMark 
Microplate Reader (Bio-Rad Laboratories).
B cell stimulation. 125Tg and WT B cells were isolated from 
spleens by negative selection using magnetic beads (Miltenyi 
Biotech) with a purity of ≥95%. The cells were plated in 
V-bottom 96-well plates (105 per well) and were cultured 
with various stimuli, including 500 ng/ml of soluble CD40 
ligand (eBioscience), 1 µg/ml LPS (Sigma-Aldrich), and 50 
ng/ml recombinant murine IL-4, IL-21, and IFN-γ (Pepro-
Tech). After incubation for 18 h, the plates were washed with 
cold media three times, and the B cells were used for anti-
gen presentation assays.
Antigen presentation assay. FACS-sorted GC and non-GC B 
cells (2 × 104 per well in Fig. 6 [A and D] and 105 per well in 
Fig. 6 B) were cultured with T cell hybridomas in the pres-
ence of 50 µM insulin or 10 µM of the B:9-23 peptide (SHL 
VEA LYL VCG ERG). In Fig. 7 (A and B), 125Tg and WT B 
cells (5 × 104 per well) were cultured with T cell hybridomas 
in the presence of serially diluted insulin. In all of the assays, 
T cell hybridomas (5 × 104 per well) were cultured with 
APCs in round-bottom 96-well plates. After incubation for 
18 h, the culture supernatant from each well was collected 
and used to culture the IL-2–dependent cell line CTLL-2 
(104 per well). The proliferation of CTLL-2 cells was assessed 
by [3H]thymidine incorporation.
Adoptive transfer and diabetes monitoring. FACS-sorted 
naive T cells (CD4+CD8−B220−CD25−CD62LhiCD44−) 
from 8F10.Rag1−/− or BDC2.5 mice were transferred i.v. 
into 4–8-wk-old NOD.Rag1−/− recipients (2 × 105 per 
mouse). In some experiments, the T cells were cotransferred 
with 2 × 106 FACS-sorted B cells (CD19+CD4−CD8−IgMa+ 
GL7−IgG−) from VH125SD or WT NOD mice. Blood glucose 
was monitored daily or weekly (Chemstrip 2GP; Roche), and 
the mice were considered diabetic with a blood glucose level 
of ≥250 mg/dl for two consecutive measurements.
RNA isolation and quantitative RT-PCR. Total RNA was iso-
lated from FACS-sorted naive and Tfh cells using the Am-
bion RNAqueous-Micro kit (Thermo Fisher Scientific) 
according to the manufacturer’s instructions. The cDNA was 
generated using the iScript Reverse Transcription Supermix 
(Bio-Rad Laboratories). Quantitative RT-PCR was per-
formed using the PerfeCTa SYBR green Fast Mix (Quanta 
Biosciences) on a StepOnePlus Real-Time PCR system 
running StepOne software.
Statistics. The log-rank (Mantel-Cox) test was used to deter-
mine significant differences in diabetes incidence. The 
Mann-Whitney U test was used to determine significant dif-
ferences between individual biological replicate samples. The 
paired Student’s t test was used to calculate p-values of each 
paired independent experiment with pooled mice.
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